AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes

Why is Kraft Heinz removing artificial dyes by 2027? How will Senate tax bill affect renewable energy stocks? What caused JetBlue to cut flights amid weak demand? Why did JPMorgan raise its Sapphire Reserve card fee? How is Trump’s Iran stance impacting oil prices? What’s behind Meta adding ads to WhatsApp now? Why is OpenAI’s partnership with Microsoft strained?

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes

benzinga.com/news/health-care/25/06/45975622/abbvies-cancer-drug-venetoclax-falls-short-in-phase-3-combination-trial-for-myelodysplastic-synd

AbbVie Inc (NYSE:ABBV) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
MDS is a group of cancers in which the bone marrow doesn’t produce enough…

This story appeared on benzinga.com, 2025-06-17 14:43:52.